BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:2024 was pivotal for TCR therapies. Following the commercial a
 pproval for Adaptimmune's Tecelra\, positive clinical readouts\, and FIH 
 trials from Immatics\, Triumvira\, Affini-T\, CDR-Life\, and TScan\, alon
 g with a wealth of investment and partnerships amounting to over $700M\, 
 it's time to come together to relish in these breakthroughs\, while pouri
 ng this energy into expanding TCR treatment potential.\n\nThe 6th TCR-Bas
 ed Therapies Summit returns as the only TCR-specific platform for industr
 y experts to join forces to share the technical insights to transform dis
 covery\, translation\, R and D\, and clinical development for cell- and b
 iologic-based approaches.\n\nProviding an unmatched close-knit collaborat
 ion environment created specifically with and for the TCR community to co
 nnect\, and learn from leaders such as Immunocore\, Immatics\, Marengo\, 
 TScan\, Medigene\, and BioNTech\, in a bid to validate novel target antig
 ens\, discover safe\, potent and optimized TCRs\, boost durability in the
  solid TME\, and delve into clinical data\, to deliver to more patient po
 pulations and achieve clinical validation.\n\nDate and Time: Tuesday\, 01
  April 2025 at 08:00 to Thursday\, 03 April 2025 at 16:30\n
DTEND:20250403T163000
DTSTAMP:20260307T153450Z
DTSTART:20250401T080000
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, Massach
 usetts\, 02116\,
SEQUENCE:0
SUMMARY:2024 was pivotal for TCR therapies. Following the commercial appro
 val for Adaptimmune's Tecelra\, positive clinical readouts\, and FIH tria
 ls from Im...
UID:28b0e4ed-ee56-40a0-9a4e-e2e3303fe937
END:VEVENT
END:VCALENDAR